Prestimulation Parameters Predicting Live Birth in Anovulatory WHO Group II Patients Undergoing Ovulation Induction with Gonadotrophins

Overview

Journal Hum Reprod

Publisher Oxford University Press

Specialty Reproductive Medicine

Date 2010 Jun 5

PMID 20522443

Citations 3

Authors

A Nyboe Andersen

A H Balen

P Platteau

G Pettersson

J-C Arce

Affiliations

Soon will be listed here.

Abstract

Background: The objective of this study was to identify baseline predictors of live birth in anovulatory patients undergoing ovulation induction, and based on these predictors, develop nomograms for estimation of the probability of live birth in a single cycle.

Methods: Univariate and multivariate logistic regression were used for retrospective analysis of clinical, sonographic and endocrinological parameters collected prior to the start of ovarian stimulation in a cohort of anovulatory World Health Organization (WHO) Group II patients (n = 335), who were resistant to clomiphene citrate (CC) and therefore stimulated with gonadotrophins using a low-dose step-up protocol.

Results: The univariate analysis identified age [OR = 0.91 (95% CI: 0.84-0.98), P = 0.015], duration of infertility [OR = 0.71 (95% CI: 0.56-0.91), P = 0.007], serum follicle stimulating hormone (FSH) concentration at the start of stimulation [OR = 0.83 (95% CI: 0.69-0.99), P = 0.034] and menstrual cycle pattern (P = 0.022) as significant predictors of live birth. Baseline concentrations of luteinizing hormone, androgens, glucose and insulin, as well as body mass index, were not predictors of live birth. In the multivariate analysis, duration of infertility, FSH and menstrual cycle pattern were independent predictors, and nomograms were designed with these three parameters for individual prediction of the probability of live birth.

Conclusions: The chances of live birth in women with WHO Group II anovulatory infertility resistant to CC undergoing ovulation induction with gonadotrophins is highly influenced by the menstrual cycle pattern. Increases in duration of infertility and concentration of FSH (within the normal range) before the start of stimulation have negative influences on the likelihood of achieving a live birth.

Citing Articles

Progress of the application clinical prediction model in polycystic ovary syndrome.

Guixue G, Yifu P, Yuan G, Xialei L, Fan S, Qian S J Ovarian Res. 2023; 16(1):230.

PMID: 38007488 PMC: 10675861. DOI: 10.1186/s13048-023-01310-2.

Pregnancy Outcomes in Women with PCOS: Follow-Up Study of a Randomized Controlled Three-Component Lifestyle Intervention.

Dietz de Loos A, Jiskoot G, Louwers Y, Beerthuizen A, Busschbach J, Laven J J Clin Med. 2023; 12(2).

PMID: 36675355 PMC: 9867443. DOI: 10.3390/jcm12020426.

Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial.

Ghanem M, Elboghdady L, Hassan M, Helal A, Gibreel A, Houssen M J Assist Reprod Genet. 2013; 30(11):1477-85.

PMID: 24014214 PMC: 3879942. DOI: 10.1007/s10815-013-0090-2.

References

Imani B, Eijkemans M, Faessen G, Bouchard P, Giudice L, Fauser B . Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril. 2002; 77(1):83-90. DOI: 10.1016/s0015-0282(01)02928-4. View

Templeton A, Morris J, Parslow W . Factors that affect outcome of in-vitro fertilisation treatment. Lancet. 1996; 348(9039):1402-6. DOI: 10.1016/S0140-6736(96)05291-9. View

Li H, van Esch M, De Vries J, Duncan W, Anderson R . Gonadotrophin ovulation induction is a successful treatment for World Health Organisation Group II anovulatory subfertility in women aged up to 40 and with body mass index up to 34. Hum Fertil (Camb). 2010; 13(1):35-40. DOI: 10.3109/14647270903490765. View

Imani B, Eijkemans M, Te Velde E, Habbema J, Fauser B . Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1999; 84(5):1617-22. DOI: 10.1210/jcem.84.5.5705. View

Eijkemans M, Imani B, Mulders A, Habbema J, Fauser B . High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod. 2003; 18(11):2357-62. DOI: 10.1093/humrep/deg459. View

Mulders A, Eijkemans M, Imani B, Fauser B . Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reprod Biomed Online. 2003; 7(2):170-8. DOI: 10.1016/s1472-6483(10)61747-6. View

van Wely M, Bayram N, van der Veen F, Bossuyt P . Predicting ongoing pregnancy following ovulation induction with recombinant FSH in women with polycystic ovary syndrome. Hum Reprod. 2005; 20(7):1827-32. DOI: 10.1093/humrep/deh891. View

. Use of clomiphene citrate in women. Fertil Steril. 2006; 86(5 Suppl 1):S187-93. DOI: 10.1016/j.fertnstert.2006.08.023. View

Kousta E, White D, Franks S . Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997; 3(4):359-65. DOI: 10.1093/humupd/3.4.359. View

10.

. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008; 23(3):462-77. DOI: 10.1093/humrep/dem426. View

11.

Fauser B, Diedrich K, Devroey P . Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2007; 14(1):1-14. DOI: 10.1093/humupd/dmm034. View

12.

Messinis I, Milingos S . Current and future status of ovulation induction in polycystic ovary syndrome. Hum Reprod Update. 1997; 3(3):235-53. DOI: 10.1093/humupd/3.3.235. View

13.

Hendriks D, Mol B, Bancsi L, Te Velde E, Broekmans F . Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril. 2005; 83(2):291-301. DOI: 10.1016/j.fertnstert.2004.10.011. View

14.

Rausch M, Legro R, Barnhart H, Schlaff W, Carr B, Diamond M . Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009; 94(9):3458-66. PMC: 2741722. DOI: 10.1210/jc.2009-0545. View

15.

Imani B, Eijkemans M, Te Velde E, Habbema J, Fauser B . Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998; 83(7):2361-5. DOI: 10.1210/jcem.83.7.4919. View

16.

Platteau P, Nyboe Andersen A, Balen A, Devroey P, Sorensen P, Helmgaard L . Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod. 2006; 21(7):1798-804. DOI: 10.1093/humrep/del085. View

17.

Mulders A, Laven J, Eijkemans M, Hughes E, Fauser B . Patient predictors for outcome of gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility: a meta-analysis. Hum Reprod Update. 2003; 9(5):429-49. DOI: 10.1093/humupd/dmg035. View

18.

Balen A, Platteau P, Andersen A, Devroey P, Sorensen P, Helmgaard L . The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. BJOG. 2006; 113(10):1195-202. DOI: 10.1111/j.1471-0528.2006.01034.x. View

19.

Balen A, Platteau P, Nyboe Andersen A, Devroey P, Helmgaard L, Arce J . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Hum Reprod. 2007; 22(7):1816-23. DOI: 10.1093/humrep/dem075. View

20.

Homburg R . Clomiphene citrate--end of an era? A mini-review. Hum Reprod. 2005; 20(8):2043-51. DOI: 10.1093/humrep/dei042. View